Top Liver Expert Joins AI Firm to Revolutionize Disease Detection

SAN MATEO, Calif. & DALLAS – April 02, 2026 – In a move that signals a significant convergence of clinical expertise and artificial intelligence, biotech firm Curve Biosciences has appointed Dr. Amit Singal as its new Chief Medical Officer. The appointment brings one of the nation's foremost authorities on liver cancer and chronic liver disease from the pinnacle of academic medicine to the front lines of diagnostic innovation, a decision that could accelerate the quest for earlier, more accurate disease detection.

Dr. Singal, who has spent his career focused on diagnosing and treating liver cancer before it becomes incurable, will now lead the clinical strategy for a company aiming to do just that on a massive scale. Curve Biosciences, which describes itself as the “Whole-Body Intelligence™ company,” is developing blood tests it claims can identify chronic diseases far earlier than current methods. By bringing Dr. Singal on board, the San Mateo-based startup gains not only a world-class clinical leader but also a powerful validation of its ambitious mission to transform patient care for one of the world's most pressing silent killers.

A Clinical Titan Enters the Biotech Arena

Dr. Singal’s transition from a towering figure in academic medicine to a biotech executive is a noteworthy event in the healthcare industry. His resume reads like a catalog of excellence in hepatology. Until this appointment, he served as the Chief of Hepatology and Professor of Internal Medicine at the prestigious University of Texas Southwestern Medical Center. There, he also held the Willis C. Maddrey, M.D. Distinguished Chair in Liver Disease and served as Medical Director of the UT Southwestern Liver Tumor Program.

His research, backed by multiple grants from the National Institutes of Health (NIH), has been laser-focused on the entire hepatocellular carcinoma (HCC) care continuum—from prevention and screening to early detection and survivorship. This deep focus on catching liver cancer in its nascent stages is precisely what makes his move to Curve so synergistic. With over 300 peer-reviewed publications in top-tier journals and a host of accolades, including Investigator Awards from the International Liver Cancer Association (ILCA) and the American Gastroenterological Association (AGA), Dr. Singal is a recognized innovator in his field.

“Amit is one of the world’s leading authorities on chronic liver disease across the full continuum of care, from prevention and screening to early detection and treatment,” said Ritish Patnaik, Ph.D., CEO and Co-Founder of Curve Biosciences, in a statement. “His expertise at the intersection of clinical medicine, population health, and translational research will be instrumental as we accelerate development of our programs.”

The Quest for 'Whole-Body Intelligence'

Curve Biosciences is entering a competitive but vital market. The global burden of chronic liver disease, driven by factors like obesity and alcohol consumption, is immense. Conditions like non-alcoholic steatohepatitis (NASH) and cirrhosis often progress silently for years, with many patients only diagnosed at an advanced stage when liver damage is irreversible or cancer has developed. This diagnostic gap represents a critical unmet need.

The current standard of care has significant limitations. Standard blood tests for liver enzymes can be unreliable indicators of underlying disease, while the definitive diagnostic tool, the liver biopsy, is invasive, costly, and carries risks. Curve Biosciences proposes to bypass these challenges with its proprietary technology. The company claims to have created the “first molecular blueprint of the human body” by curating a massive collection of tissue samples into a “Whole-Body Atlas.” Using this atlas, its AI-driven “Whole-Body Intelligence” models are designed to analyze a simple blood sample and detect the subtle molecular signals of chronic disease far earlier and more accurately.

While the company’s vision is compelling, public details on its technology, funding status, and the validation of its “Whole-Body Blood Tests” remain limited. This is not uncommon for privately held biotech firms in the early stages of development, where intellectual property is closely guarded. However, the lack of extensive public data places even greater weight on the credibility of its leadership. The recruitment of a clinical leader of Dr. Singal's stature is a strategic move that speaks volumes, suggesting that the underlying science was compelling enough to attract a top expert from a secure and prestigious academic post.

A Paradigm Shift in Early Detection?

The partnership between Dr. Singal and Curve Biosciences embodies a powerful trend in modern medicine: the fusion of deep clinical knowledge with cutting-edge data science. Dr. Singal's role will be to shepherd Curve's promising technology through the rigorous process of clinical validation, designing and overseeing the trials necessary to prove its efficacy and utility in real-world patient care.

His motivation appears deeply rooted in his clinical experience. “I have spent my career working to close the gaps in liver care, particularly in clinical settings where we have the greatest opportunity to change outcomes,” Dr. Singal stated. “Far too many patients progress to a stage of liver disease when curative options are no longer possible. Curve Biosciences is advancing innovative approaches designed to shift that paradigm. I am excited to join the team and help translate scientific innovation into practical tools that can improve survival and quality of life for patients with liver disease.”

This sentiment highlights the potential for a fundamental change in medical practice. If successful, tools like the ones Curve is developing could shift the focus of liver care from managing late-stage complications to proactive, early intervention. A simple, reliable blood test could be used to screen at-risk populations, identify individuals with early-stage fibrosis or inflammation, and guide preventative therapies long before symptoms appear, potentially saving countless lives and reducing the immense economic burden of advanced liver disease.

The Path from Lab to Clinic

Despite the immense promise, the road ahead for Curve Biosciences is challenging. The journey from a promising diagnostic concept to a widely adopted clinical tool is fraught with scientific, regulatory, and commercial hurdles. The company’s “Whole-Body Blood Tests” will need to undergo extensive clinical trials to demonstrate not only analytical validity (does the test measure what it claims to measure?) but also clinical validity (does the test correlate with a clinical condition?) and, most importantly, clinical utility (does using the test improve patient outcomes?).

Navigating the complex regulatory landscape of the U.S. Food and Drug Administration (FDA) for novel diagnostics is a formidable task that requires meticulous data and strategic planning. This is precisely where Dr. Singal's expertise will be indispensable. His decades of experience designing and running clinical studies, coupled with his intimate knowledge of the liver disease patient journey, will be critical in shaping a clinical development program that can meet the high bar set by regulators, clinicians, and payers.

The appointment of Dr. Singal is a clear statement of intent from Curve Biosciences. It suggests a commitment to rigorous scientific validation and a deep understanding that even the most sophisticated AI is meaningless without a clear path to improving human health. For a field desperately in need of better tools, this partnership represents a significant and hopeful step toward a future where chronic liver disease can be managed, and perhaps even defeated, through the power of early detection.